Dolamvir 50 mg, 300 mg, 300 mg, Tablets
PDF Leaflet Revision Date: 10 October 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults aged 18 years and older.
Dosage (summary)
One tablet orally, once daily, without regard to food.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential for neural tube defects.
Key Drug Interactions
- Rifampicin decreases dolutegravir levels
- Metformin contraindicated
Contraindications
- Hypersensitivity
- Moderate/severe hepatic impairment
- Renal impairment (creatinine clearance < 80 mL/min)
- Pregnancy
- Lactation
Common side effects
- Nausea
- Fatigue
- Headache
- Rash
- Lactic acidosis
Counselling Points
- Monitor for signs of lactic acidosis
- Use effective contraception in women of childbearing age
- Regular liver function tests recommended
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Risk of opportunistic infections
Important Disclaimer
The Dolamvir 50 mg, 300 mg, 300 mg, Tablets professional information leaflet below is the property of Novagen Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
